Survival benefit of deceased donor kidney transplantation versus continued dialysis
A more visual summary of the target trial emulation and relevant context (just 7 images to look at!). Infographics by Anca Stefan and Cristina Popa
TARGET TRIAL: The Visual Abstract
TARGET trial: El Resumen Visual
Can Dialysis Outshine Transplant in the Elderly?
This week, we will discuss whether decreased donor transplantation improves mortality in all patients. In this target trial emulation standard donor, extended donor, donation after brain death and donation after cardiac death outcomes are compared across age groups with different co-morbid conditions.
START trial on Instagram
START trial on Instagram
A more visual summary of the trial and relevant context (just 6 images to look at!). Infographics by Farah Wehbe
Raising sodium: can tolvaptan rival 3% hypertonic saline?
Why Can’t I Quit You: Steroid Tapering in Adults with Podocytopathies (START)
START: The Visual Abstract
START: El Resumen Visual
NephJC on LinkedIn
NephJC is now more than twelve years old- and it’s amazing to see how far a simple idea has grown. We started with a handful of nephrologists on Twitter (yeah, we still call it that) choosing a paper and discussing it in cyberspace on social media, with access for all. Those conversations were lively, joyful, and full of curiosity.
Over time, that spark became a community: nephrologists, trainees, students, researchers, and patients learning together through article summaries, visual abstracts, podcasts, book clubs, and even an internship- to give back to our community and support the next generation of educators.
Unfortunately, but inevitably, social media has changed. The platforms that once felt like bustling town squares now feel scattered, quieter, and harder to gather interest from a worldwide audience. Our community is more spread out than ever- and we’re trying to meet nephrologists wherever they are today, hoping to catch a small glimpse of the energy we once shared.
So, we’re happy to announce that NephJC now has a LinkedIn page.
If you want to stay connected and if LinkedIn is your preferred social media medium, follow us there- we’d love to keep the conversation going, wherever it chooses to live next.
2026 NephJC Night in Denver
NephJC 2026 Fall Pledge Drive
REFINe-ing AI’s Role in Nephrology Diagnosis
REFINe: The Visual Abstract
REFINe: El Resumen Visual
ARISE FLUIDS: Early vasopressors or more fluids in early septic shock?
Dietary nitrate supplementation in CKD pregnancy
Is this the end of the beta-blocker debate in hemodialysis?
MERCURI-2 on Instagram
Too sweet to be true? Prophylactic SGLT2 inhibitors before cardiac surgery
MERCURI-2 reports that dapagliflozin cuts postoperative AKI after cardiac surgery, but the headline result is mostly a urine-output story, not a creatinine one. That matters: urine output after surgery is easily swayed by anesthesia, fluid shifts, vasopressors, and a diuretic drug in the mix. Until dapagliflozin shows it protects kidney function, not just urine output.